Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

We prospectively evaluated the efficacy and safety of imatinib plus hydroxyurea in patients with progressive/recurrent meningioma. A total of 21 patients with progressive/recurrent meningioma were enrolled in this dual center, single-arm, phase II trial. All patients received 500 mg of hydroxyurea t...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Reardon, David A., Norden, Andrew D., Desjardins, Annick, Vredenburgh, James J., Herndon, James E., Coan, April, Sampson, John H., Gururangan, Sridharan, Peters, Katherine B., McLendon, Roger E., Norfleet, Julie A., Lipp, Eric S., Drappatz, Jan, Wen, Patrick Y., Friedman, Henry S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2011
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3616615/
https://ncbi.nlm.nih.gov/pubmed/21938530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-011-0687-1
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi